Olivia Brown appointed to lead neurotoxin franchise at Ipsen

Biopharmaceutical company Ipsen announced the appointment of Olivia Brown as Executive Vice President, Global Head of Neurotoxins, effective April 1, 2025. Olivia Brown joins the leadership team, reporting to David Loew, Chief Executive Officer. Her role will be to lead the strategy and execution of therapeutic and aesthetic indications for Ipsen's neurotoxins franchise.

With over 20 years of experience, including at Novartis, Merz Aesthetics, and Galderma, Olivia Brown will help strengthen Ipsen's neurotoxins practice, an area where the company already has a strong presence. Ipsen is leveraging its recombinant neurotoxin LANT program to potentially deliver better patient outcomes.